Do parasite infections interfere with immunisation? A review and meta-analysis

Wait, Liana F.; Dobson, Andrew; Graham, Andrea L.

doi:10.1016/j.vaccine.2020.06.064

Cited by 43 publications

(54 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Free-roaming dogs are generally malnourished as their diet is of low quality and/or quantity, having a negative impact on immunity ( 52 , 53 ). Also, these animals are usually infected by endo- and ectoparasites or other immunosuppressive infectious agents ( 54 ). For example, canine distemper virus (CDV) can infect and modulate the antigen presenting properties of dendritic cells and thus influence the immune response against CDV and other concomitant infections/vaccinations ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of the Oral Rabies Vaccine Strain SPBN GASGAS in Dogs Under Field Settings in Namibia

Molini

Hassel

Ortmann³

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

Dog-mediated rabies is endemic throughout Africa. While free-roaming dogs that play a crucial role in rabies transmission are often inaccessible for parenteral vaccination during mass dog vaccination campaigns, oral rabies vaccination (ORV) is considered to be a promising alternative to increase vaccination coverage in these hard-to-reach dogs. The acceptance of ORV as an efficient supplementary tool is still low, not least because of limited immunogenicity and field trial data in local dogs. In this study, the immunogenicity of the highly attenuated 3rd-generation oral rabies vaccine strain SPBN GASGAS in local free-roaming dogs from Namibia was assessed by determining the immune response in terms of seroconversion for up to 56 days post-vaccination. At two study sites, free-roaming dogs were vaccinated by administering the vaccine either by direct oral administration or via a vaccine-loaded egg bait. Pre- and post-vaccination blood samples were tested for rabies virus neutralizing as well as binding antibodies using standard serological assays. A multiple logistic regression (MLR) analysis was performed to determine a possible influence of study area, vaccination method, and vaccine dose on the seroconversion rate obtained. About 78% of the dogs vaccinated by the oral route seroconverted (enzyme-linked immunosorbent assay, ELISA), though the seroconversion as determined by a rapid fluorescence focus inhibition test (RFFIT) was much lower. None of the factors examined had a significant effect on the seroconversion rate. This study confirms the immunogenicity of the vaccine strain SPBN GASGAS and the potential utility of ORV for the control of dog-mediated rabies in African dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunogenicity of the Oral Rabies Vaccine Strain SPBN GASGAS in Dogs Under Field Settings in Namibia

Molini

Hassel

Ortmann³

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…Dogs with low BCS were more likely to lose adequate level of binding antibodies than PLOS NEGLECTED TROPICAL DISEASES their counterpart. Early loss of adequate level of binding antibodies in dogs with low BCS score could be related with a number of factors such as parasitic burden, nutritional and general health status [12,38,39]. Parasitic infection and malnutrition is common in FRDD in Flores Island, as it is in other rabies endemic areas in developing countries, where dog owners may neither routinely apply anti-parasite treatments nor feed the dogs with adequate food [40].…”

Section: Discussionmentioning

confidence: 99%

Loss of binding antibodies against rabies in a vaccinated dog population in Flores Island, Indonesia

et al. 2021

View full text Add to dashboard Cite

Effective parenteral vaccines are available to control rabies in dogs. While such vaccines are successfully used worldwide, the period between vaccine boosters required to guarantee protection of the population against rabies varies between vaccines and populations. In Flores Island, Indonesia, internationally and locally produced rabies vaccines are used during annual vaccination campaigns of predominantly free-roaming owned domestic dogs. The study objective was to identify the duration of the presence and factors associated with the loss of adequate level of binding antibodies (≥0.5 EU/ml) following rabies vaccination in a domestic dog population on Flores Island. A total of 171 dogs that developed an antibody titre higher or equal to 0.5 EU/ml 30 days after vaccination (D30), were repeatedly sampled at day 90, 180, 270, and 360 after vaccination. On the day of vaccination (D0), an interview was performed with dog owners to collect information on dog characteristics (age, sex, body condition score (BCS)), history of rabies vaccination, kind of daily food, frequency of feeding, and origin of the dog. Serum samples were collected and the level of antibodies was quantitatively assessed using ELISA tests. Dogs were categorized as having an adequate level of binding antibodies (≥0.5 EU/ml) or inadequate level of binding antibodies (<0.5 EU/ml) at each time points examined. A total of 115, 72, 23, and 31 dogs were sampled at D90, D180, D270, and D360, respectively, with the highest proportion of antibodies ≥ 0.5 EU/ml (58%, 95% CI, 49–67%) at D90, which reduced gradually until D360 (35%, 95% CI, 19–52%). Multivariable logistic regression models showed that loss of adequate level of binding antibodies is significantly associated with dogs having no history of vaccination or vaccination applied more than 12 months before D0, being less than 12 months of age, and having a poor BCS. These results highlight the importance of BCS regarding the immune response duration and provide insights into frequency of vaccination campaigns required for the internationally available vaccine used on Flores Island. For dogs without vaccination history or vaccination being applied more than 12 months before D0, a booster is recommended within 3 months (a largest drop of antibodies was detected within the first 90 days) after the first vaccination to guarantee measurable protection of the population that lasts at least for one year.

show abstract

“…Noteworthy, in this review we focus on the concomitant parasitic (malaria and soil-transmitted helminths) and viral (Cytomegalovirus) infections which are highly prevalent among schistosomiasis endemic populations in the low and middle income countries (LMIC) (73,74). Parasitic co-infections are of particular importance due to the significant negative impact on immunization especially among parasite endemic populations which are the target for schistosomiasis vaccine trials (73).…”

Section: Co-infectionsmentioning

confidence: 99%

Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings

et al. 2021

View full text Add to dashboard Cite

Despite mass drug administration programmes with praziquantel, the prevalence of schistosomiasis remains high. A vaccine is urgently needed to control transmission of this debilitating disease. As some promising schistosomiasis vaccine candidates are moving through pre-clinical and clinical testing, we review the immunological challenges that these vaccine candidates may encounter in transitioning through the clinical trial phases in endemic settings. Prior exposure of the target population to schistosomes and other infections may impact vaccine response and efficacy and therefore requires considerable attention. Schistosomes are known for their potential to induce T-reg/IL-10 mediated immune suppression in populations which are chronically infected. Moreover, endemicity of schistosomiasis is focal whereby target and trial populations may exhibit several degrees of prior exposure as well as in utero exposure which may increase heterogeneity of vaccine responses. The age dependent distribution of exposure and development of acquired immunity, and general differences in the baseline immunological profile, adds to the complexity of selecting suitable trial populations. Similarly, prior or concurrent infections with other parasitic helminths, viral and bacterial infections, may alter immunological responses. Consequently, treatment of co-infections may benefit the immunogenicity of vaccines and may be considered despite logistical challenges. On the other hand, viral infections leave a life-long immunological imprint on the human host. Screening for serostatus may be needed to facilitate interpretation of vaccine responses. Co-delivery of schistosome vaccines with PZQ is attractive from a perspective of implementation but may complicate the immunogenicity of schistosomiasis vaccines. Several studies have reported PZQ treatment to induce both transient and long-term immuno-modulatory effects as a result of tegument destruction, worm killing and subsequent exposure of worm antigens to the host immune system. These in turn may augment or antagonize vaccine immunogenicity. Understanding the complex immunological interactions between vaccine, co-infections or prior exposure is essential in early stages of clinical development to facilitate phase 3 clinical trial design and implementation policies. Besides well-designed studies in different target populations using schistosome candidate vaccines or other vaccines as models, controlled human infections could also help identify markers of immune protection in populations with different disease and immunological backgrounds.

show abstract

Do parasite infections interfere with immunisation? A review and meta-analysis

Cited by 43 publications

References 72 publications

Immunogenicity of the Oral Rabies Vaccine Strain SPBN GASGAS in Dogs Under Field Settings in Namibia

Immunogenicity of the Oral Rabies Vaccine Strain SPBN GASGAS in Dogs Under Field Settings in Namibia

Loss of binding antibodies against rabies in a vaccinated dog population in Flores Island, Indonesia

Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings

Contact Info

Product

Resources

About